STOCK TITAN
  1. Home
  2. News
  3. TIL

Instil Bio Inc - TIL STOCK NEWS

Welcome to our dedicated news page for Instil Bio (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Instil Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Instil Bio's position in the market.

News
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Instil Bio, Inc. reported its Q4 and full year 2023 financial results, highlighting $175.0 million in total cash, a strategic collaboration for a potential trial in non-small cell lung cancer, and exploring new therapeutic candidates. The company expects its cash reserves to fund operations beyond 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
earnings
-
News
Instil Bio Announces Strategic Update
Rhea-AI Summary
Instil Bio, Inc. (NASDAQ: TIL) has announced a strategic update, including an agreement with a collaborator for preclinical manufacturing feasibility studies in the ITIL-306 program. If successful, the collaborator may open an investigator-initiated clinical trial for patients with non-small cell lung cancer in China. The company also plans to close its UK manufacturing and clinical operations to save costs and improve time efficiency. However, it will retain key personnel for early-stage pipeline development and collaboration support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
Rhea-AI Summary
Instil Bio, Inc. (NASDAQ: TIL) has announced a 1-for-20 reverse stock split of its outstanding shares of common stock to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of issued and outstanding shares from approximately 130.1 million to approximately 6.5 million, with the stock continuing to trade under the symbol 'TIL'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
News
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Instil Bio, Inc. (Nasdaq: TIL) reported its Q3 2023 financial results and corporate update, presenting novel preclinical data at SITC 2023 Annual Meeting, publishing ITIL-306 manuscript, and anticipating initial data from ITIL-306-202 Phase 1 clinical trial in 2024. Cash runway expected beyond 2026. Q3 2023 financials show a decrease in cash, cash equivalents, and marketable securities compared to December 31, 2022, with reduced research and development and general and administrative expenses. Instil has presented non-GAAP financial measures alongside GAAP figures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
earnings
-
News
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Rhea-AI Summary
Instil Bio, Inc. presented novel preclinical data at the SITC 2023 Annual Meeting demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR™) platform enhances the activity of CD4+ T cells in multiple ways. The data showed enhanced gene signatures of activation and cytotoxicity in CoStAR-transduced CD4+ T cells, suggesting that CoStAR can endow CD4+ T cells with novel cell-killing capacity. CoStAR was also shown to enhance the secretion of soluble factors from CD4+ T cells to boost the proliferation and survival of companion CD8+ T cells. These findings support the potential of CoStAR to enhance the function of TIL therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Instil Bio, Inc. (NASDAQ: TIL) reports successful manufacturing of ITIL-306 in its UK facility, doubling the number of CoStAR-TILs in the final product. Anticipates initiating phase 1 clinical trial ITIL-306-202 in 2H 2023 with initial clinical data expected in 2024. Cash runway beyond 2026 confirmed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
earnings
News
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Rhea-AI Summary
Instil Bio, Inc. presented data at the British Society for Gene and Cell Therapy Annual Conference, demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR) platform enhances the activity of tumor infiltrating lymphocytes (TILs) against autologous tumors. The data showed that Instil's FRα-CoStAR enhances the activity of TILs against ovarian, renal, and non-small cell lung cancer tumors. Initial clinical data from ITIL-306, the first CoStAR-TIL in clinical development, is anticipated in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
clinical trial
-
News
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
earnings
-
News
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
earnings
News
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
none
Stock TIL logo
Instil Bio Inc

Nasdaq:TIL

TIL Rankings

#4531 Ranked by Market Cap
#5451 Ranked by Stock Gains
N/A Ranked by Dividends

TIL Stock Data

70.86M
3.06M
6.84%
65.92%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Dallas

About TIL

instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.